FokI, BsmI, ApaI, TaqI: Four VDR Polymorphisms Explained

Background: Why VDR Polymorphisms Matter

The Vitamin D Receptor is the protein that mediates virtually all of the genomic effects of vitamin D in the human body. Once calcitriol (the active form of vitamin D) binds to this receptor, the receptor-ligand complex moves into the cell nucleus, binds to specific DNA sequences called vitamin D response elements (VDREs), and activates hundreds of downstream genes. These genes regulate everything from calcium absorption and bone mineralization to immune cell differentiation and insulin secretion.

Given this central role, it follows that genetic variants in the VDR gene can have measurable downstream effects on human physiology. Over 200 VDR polymorphisms have been identified, but four have accumulated decades of research: FokI, BsmI, ApaI, and TaqI. Each sits in a different functional region of the gene, and each influences receptor performance through a distinct mechanism.

What makes these variants particularly relevant today is that they appear in standard consumer DNA raw data files from both AncestryDNA and 23andMe. If you have taken either test, your genotype for all four is almost certainly already in your data, waiting to be interpreted. For a broader introduction to how these variants affect vitamin D absorption, see our guide on VDR gene variants and vitamin D absorption.

FokI (rs10735810): The Potency Variant

The FokI polymorphism is located at the translation initiation codon of the VDR gene, in exon 2. A single nucleotide change (C to T) at this position creates an alternative start site that produces a VDR protein three amino acids longer than the standard form.

This length difference is not trivial. The shorter "F" allele protein (produced by the CC genotype) interacts more effectively with the TFIIB component of the general transcription machinery. In practical terms, this means the receptor can more powerfully switch on vitamin D-responsive genes. The longer "f" allele protein (TT genotype) has a weaker interaction with TFIIB, resulting in reduced transcriptional output for the same amount of calcitriol.

Research published in the Journal of Clinical Investigation and elsewhere has found that individuals with the "ff" (TT) genotype require significantly more vitamin D to achieve the same biological effects as "FF" individuals. Studies of bone density, immune response, and calcium metabolism consistently show the "ff" genotype at a disadvantage relative to "FF" when vitamin D intake is equivalent.

FokI is the only one of the four variants that is in the protein-coding region of the gene. The other three are in non-coding regions and affect expression rather than protein structure.

BsmI (rs1544410): The Expression Variant

BsmI sits in intron 8, near the 3' end of the VDR gene. Intronic variants do not change the amino acid sequence of the protein, but they can still influence gene expression by affecting how pre-mRNA is processed, how stable the mature mRNA transcript is, or how efficiently the transcript is translated.

The BsmI "b" allele (GG genotype) is associated with reduced VDR mRNA stability in certain tissue types, meaning cells produce fewer receptor proteins. Fewer receptor copies in a given cell translates to reduced overall sensitivity to vitamin D signals, even when the individual receptor molecules themselves are structurally normal.

BsmI has been studied extensively in the context of bone health, cancer risk, and autoimmune disease susceptibility. A meta-analysis of over 20 studies found that the "bb" (GG) genotype was associated with statistically lower bone mineral density at the femoral neck compared to "BB" individuals, particularly in postmenopausal women.

ApaI (rs7975232): The Binding Affinity Variant

ApaI is also located in intron 8, very close to BsmI, which is why the two variants are often in strong linkage disequilibrium and tend to be analyzed together. The ApaI "a" allele (AA genotype) has been associated with altered receptor binding affinity in specific tissue types, particularly bone cells and certain immune cell populations.

While ApaI's independent functional mechanism is less definitively established than FokI's, its predictive value in combination with BsmI and TaqI is well-supported. Studies examining haplotype effects, where combinations of BsmI, ApaI, and TaqI alleles are analyzed together, consistently find that certain haplotype blocks confer substantially different bone and immune outcomes than others.

TaqI (rs731236): The Transcription Variant

TaqI is located in exon 9 of the VDR gene and represents a synonymous substitution, meaning the nucleotide change does not alter the amino acid sequence of the protein. At first glance this might suggest it has no functional consequence, but synonymous variants can significantly affect mRNA secondary structure, translational speed, and codon usage efficiency.

TaqI is particularly well-documented for its association with calcium transport gene expression. Specifically, genes encoding the calcium transport proteins TRPV5, TRPV6, and calbindin-D9k are differentially regulated depending on TaqI genotype. The "t" allele (CC genotype) is associated with lower expression of these transport genes, which has been measured in intestinal biopsy studies.

TaqI also has strong associations with bone mineral density outcomes and has been studied extensively in relation to fracture risk across multiple ethnic populations.

How the Four Variants Interact: The Haplotype Effect

Analyzing each variant in isolation gives you part of the picture. But because BsmI, ApaI, and TaqI are located close together on chromosome 12 and are in strong linkage disequilibrium, they tend to be inherited as a unit. Researchers study these combinations as "haplotypes," and the most commonly studied are the "BAt" haplotype (b, a, t alleles together) and the "baT" haplotype.

Studies have found that the overall pattern of your four VDR variant alleles predicts outcomes more reliably than any single variant alone. For example, a person carrying the "ff" FokI genotype along with the unfavorable BsmI-ApaI-TaqI haplotype has a substantially different vitamin D biology than someone who carries only one unfavorable variant while the others are normal.

Population Frequencies

These variants are common. They are not rare mutations but rather normal genetic variation present at significant frequencies across all human populations. Some population-level data:

• FokI "ff" (TT genotype): approximately 25-30% of individuals of European ancestry; frequencies vary considerably across populations
• BsmI "bb" (GG genotype): approximately 30-40% in European populations
• TaqI "tt" (CC genotype): approximately 20-35% depending on ancestry

This means that between 20% and 40% of the general population may carry at least one homozygous "impaired sensitivity" genotype across these four variants, with a meaningful subset carrying two or more. Given how rarely this gets factored into clinical vitamin D protocols, it represents a significant knowledge gap in routine practice.

Practical Implications

Understanding your specific genotype combination for all four variants allows for a much more targeted approach to vitamin D optimization. Instead of using a one-size population reference range as your target, you can aim for the serum 25(OH)D level that actually produces the biological effects you need, and you can prioritize the cofactors that matter most for your specific receptor profile.

For someone with an impaired FokI genotype, ensuring adequate zinc is particularly important since zinc is structural to the DNA-binding domain of the VDR protein itself. For someone with impaired TaqI function, prioritizing vitamin K2 to support calcium transport genes becomes especially relevant. And for everyone with any degree of VDR impairment, magnesium is the foundational cofactor that cannot be overlooked.